Blog
RSS FeedPosted by Michael Wonder on 05 Jul 2018
B.C. charity fights feds for access to life-saving medicine
5 July 2018 - Cure SMA Canada is urging the federal government to reimburse the costs of Spinraza. ...
Posted by Michael Wonder on 05 Jul 2018
Survey shows public support for NHS tax rise
5 July 2018 - The vast majority of the public would be willing to accept tax increases to secure significant ...
Posted by Michael Wonder on 05 Jul 2018
MSD’s anti-viral Prevymis fails to win NICE backing
4 July 2018 - MSD’s Prevymis has not won the support of NHS cost regulators for preventing cytomegalovirus reactivation and ...
Posted by Michael Wonder on 05 Jul 2018
PBS cost recovery implementation statement (2018-2019)
5 July 2018 - PBS and NIP cost recovery – annual indexation of fees. ...
Posted by Michael Wonder on 04 Jul 2018
New osteoporosis treatment set to provide another option for patients
5 July 2018 - Another press release from PHARMAC announcing the listing of a new medicine that should have occurred ...
Posted by Michael Wonder on 04 Jul 2018
Two of three US pharma companies receive Independence Day treat from NICE
4 July 2018 - NICE has released its final appraisal determinations for Tesaro, Pfizer and BMS cancer medicines. ...
Posted by Michael Wonder on 04 Jul 2018
‘Gravy train’ of private health to run off rails
5 July 2018 - Australia’s private healthcare sector is set to come under further pressure, with the “gravy train” fast ...
Posted by Michael Wonder on 04 Jul 2018
Nation's first free meningococcal B vaccination program to be funded in South Australia
4 July 2018 - South Australian babies and young people will be the first in the nation to receive free ...
Posted by Michael Wonder on 04 Jul 2018
PBAC to adopt a revised approach to considering brand equivalence/substitution for biosimilar medicines
4 July 2018 - PBAC to consult with Medicines Australia on the possible withdrawal of the TGA-PBAC parallel process for ...
Posted by Michael Wonder on 03 Jul 2018
PBAC rejects first submission supported by real-world evidence
4 July 2018 - A retrospective chart review of 211 Australian patients with chronic migraine served as the key evidentiary basis ...
Posted by Michael Wonder on 03 Jul 2018
NICE says Tookad too expensive for prostate cancer
3 July 2018 - The National Institute for Health and Care Excellence has concluded that Steba Biotech’s Tookad is not ...
Posted by Michael Wonder on 02 Jul 2018
Haemophilia A and sialorrhoea: contemporary comparative therapies not implemented so added benefit not proven
2 July 2018 - Of the four dossier evaluations published by the IQWiG on 2 July, two have a striking similarity ...
Posted by Michael Wonder on 02 Jul 2018
Another multi-product proposal from Novartis, this time involving ten pharmaceuticals
2 July 2018 - PHARMAC is seeking feedback on a proposal to fund five new treatments, widen access to three ...
Posted by Michael Wonder on 02 Jul 2018
Is nudging biologic patients towards biosimilars a good choice for plan sponsors?
29 June 2018 - A recent study examining the potential savings determined that, based on the uptake of available biosimilars ...
Posted by Michael Wonder on 01 Jul 2018
Private health insurance a hard sell to Medicare generation
30 June 2018 - The Coalition’s health insurance reforms are needed to prevent a decade-long decline in the sector, according ...